EAM Investors’s Supernus Pharmaceuticals SUPN Stock Holding History

EAM Investors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-66,030	Closed	-$2.36M	–	362
2022 Q4	$2.36M	Buy	66,030 +31,004	+89%	+$1.08M	0.49%	66
2022 Q3	$1.19M	Buy	+35,026	New	+$1.14M	0.26%	172
2018 Q3	–	Sell	-53,910	Closed	-$3.23M	–	365
2018 Q2	$3.23M	Buy	+53,910	New	+$2.79M	0.51%	73
2017 Q4	–	Sell	-58,967	Closed	-$2.36M	–	343
2017 Q3	$2.36M	Sell	58,967 -17,725	-23%	-$767K	0.31%	143
2017 Q2	$3.31M	Buy	+76,692	New	+$2.73M	0.55%	55
2016 Q4	–	Sell	-143,679	Closed	-$3.55M	–	362
2016 Q3	$3.55M	Sell	143,679 -44,598	-24%	-$1.01M	0.48%	49
2016 Q2	$3.83M	Buy	+188,277	New	+$3.34M	0.58%	22
2016 Q1	–	Sell	-236,833	Closed	-$3.18M	–	341
2015 Q4	$3.18M	Buy	236,833 +21,568	+10%	+$334K	0.42%	96
2015 Q3	$3.02M	Sell	215,265 -58,252	-21%	-$1.08M	0.48%	59
2015 Q2	$4.64M	Buy	+273,517	New	+$3.89M	0.54%	39

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM Investors's SUPN Position: Q1 2023 in Review

EAM Investors sold out of Supernus Pharmaceuticals (SUPN) in Q1 2023, closing a stake of 66,030 shares — an estimated $2.36M sold.

EAM Investors first reported a position in SUPN in Q2 2015 and held it in 10 quarters. The position peaked at $4.64M in Q2 2015. 258 funds tracked by Wall St. Rank hold SUPN as of Q1 2023.

EAM Investors reported no remaining Supernus Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
EAM Investors sold 66,030 Supernus Pharmaceuticals shares in Q1 2023, an estimated $2.36M.
EAM Investors first reported a position in Supernus Pharmaceuticals in Q2 2015 and held it in 10 quarters.
EAM Investors's Supernus Pharmaceuticals position peaked at $4.64M in Q2 2015.
258 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2023.

Based on EAM Investors's 13F filing for Q1 2023, filed 15 May 2023.